BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
Figure out How to Remain Informed about the Most recent Open Record Extra Offers - 2Instructions to Choose the Best Material Organization for a Fruitful Rooftop Substitution
- 3Photos: Presidential turkey pardons — a look back
- 4How AI fixed the James Webb Space Telescope's blurry vision
- 5Understanding Successful Compromise Standards to Cultivate Agreeable Connections
- 6 Famous Cell phone Brands All over The Planet
- French lawmakers narrowly approve health care budget, suspending Macron's flagship pension reform
- Dental Embed Innovation: An Achievement in Helpful Dentistry
- Surveys of 6 Hot Savvy Beds
- The most effective method to Amplify Your Opportunity for growth in a Web-based Degree Program
- Which '80s Film Actually Holds Up Today?
- How food assistance programs can feed families and nourish their dignity
- See the famous winged horse Pegasus fly in the autumn night sky
- Extraordinary Picks for Home Apparatuses: Making Life Simpler
